Company intelligence / Profile preview
BTG
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
BTG developed and commercialized a portfolio of specialty pharmaceuticals and interventional medicine products, including antitoxins for digoxin overdose and snake envenomation and multiple embolization and interventional oncology devices; its key drugs reached full commercial stage with several approvals in the United States and other markets.[1][2]
- Therapeutic areas
- OtherWomen's HealthEndocrinologyCardiovascularPsychiatryOncologyMen's Health
- Modalities
- Small moleculeMonoclonal antibodyAntitoxinDeviceRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on BTG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BTG.